Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

384 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Feasibility and effectiveness in clinical practice of a multifactorial intervention for the reduction of cardiovascular risk in patients with type 2 diabetes: the 2-year interim analysis of the MIND.IT study: a cluster randomized trial.
Vaccaro O, Franzini L, Miccoli R, Cavalot F, Ardigò D, Boemi M, De Feo P, Reboldi G, Rivellese AA, Trovati M, Zavaroni I; MIND.IT Study Group. Vaccaro O, et al. Diabetes Care. 2013 Sep;36(9):2566-72. doi: 10.2337/dc12-1781. Epub 2013 Jul 17. Diabetes Care. 2013. PMID: 23863908 Free PMC article. Clinical Trial.
Continuous subcutaneous insulin infusion in Italy: third national survey.
Bruttomesso D, Laviola L, Lepore G, Bonfanti R, Bozzetto L, Corsi A, Di Blasi V, Girelli A, Grassi G, Iafusco D, Rabbone I, Schiaffini R; Italian Study Group on Diffusion of CSII. Bruttomesso D, et al. Diabetes Technol Ther. 2015 Feb;17(2):96-104. doi: 10.1089/dia.2014.0242. Epub 2014 Dec 5. Diabetes Technol Ther. 2015. PMID: 25479035 Free article.
Factors associated with improved glycemic control following continuous subcutaneous insulin infusion therapy in patients with type 2 diabetes uncontrolled with bolus-basal insulin regimens: An analysis from the OpT2mise randomized trial.
Metzger M, Castañeda J, Reznik Y, Giorgino F, Conget I, Aronson R, de Portu S, Runzis S, Lee SW, Cohen O. Metzger M, et al. Among authors: giorgino f. Diabetes Obes Metab. 2017 Oct;19(10):1490-1494. doi: 10.1111/dom.12960. Epub 2017 Jul 25. Diabetes Obes Metab. 2017. PMID: 28374511 Clinical Trial.
Effect of once-weekly dulaglutide on glycated haemoglobin (HbA1c) and fasting blood glucose in patient subpopulations by gender, duration of diabetes and baseline HbA1c.
Gallwitz B, Dagogo-Jack S, Thieu V, Garcia-Perez LE, Pavo I, Yu M, Robertson KE, Zhang N, Giorgino F. Gallwitz B, et al. Among authors: giorgino f. Diabetes Obes Metab. 2018 Feb;20(2):409-418. doi: 10.1111/dom.13086. Epub 2017 Oct 5. Diabetes Obes Metab. 2018. PMID: 28817231 Free PMC article. Clinical Trial.
Metabolic control and complications in Italian people with diabetes treated with continuous subcutaneous insulin infusion.
Lepore G, Bonfanti R, Bozzetto L, Di Blasi V, Girelli A, Grassi G, Iafusco D, Laviola L, Rabbone I, Schiaffini R, Bruttomesso D; Italian Study Group on the Diffusion of CSII. Lepore G, et al. Nutr Metab Cardiovasc Dis. 2018 Apr;28(4):335-342. doi: 10.1016/j.numecd.2017.12.001. Epub 2017 Dec 9. Nutr Metab Cardiovasc Dis. 2018. PMID: 29428572
Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study.
Fioretto P, Del Prato S, Buse JB, Goldenberg R, Giorgino F, Reyner D, Langkilde AM, Sjöström CD, Sartipy P; DERIVE Study Investigators. Fioretto P, et al. Among authors: giorgino f. Diabetes Obes Metab. 2018 Nov;20(11):2532-2540. doi: 10.1111/dom.13413. Epub 2018 Jul 10. Diabetes Obes Metab. 2018. PMID: 29888547 Free PMC article. Clinical Trial.
384 results